Compare Quest Diagnostics Inc (DGX) vs IONQ Inc (IONQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs IONQ Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while IONQ Inc trades at $39.89 (market cap $15.98B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while IONQ Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and IONQ Inc for 33 Days on average.
| DGX | IONQ | |
|---|---|---|
Market Cap | $25.48B | $15.98B |
Volume | 941,866 | 22,848,240 |
Sector | Health | Technology |
52-Week High | $247.45 | $82.09 |
52-Week Low | $173.49 | $26.59 |
Typical Hold Time | 56 Days | 33 Days |
Enterprise Value | $31.23B | $13.92B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
IONQ trades at $39.89, down 3.51% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported revenue of $130.02M in 2025 but a net loss of $510.38M, with a high P/S ratio of 54.74. Recent news highlights Bank of America's Buy rating and $60 price target, citing IonQ's semiconductor-based quantum computing approach as a key growth driver.
The stock presents high-risk, high-reward potential with strong analyst optimism but faces significant execution risks amid widening losses. Upside depends on scaling quantum technology profitably, while downside risks include cash burn and competitive threats. The consensus price target of $62.75 suggests substantial upside if growth targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →
